08/06/12 - 07:00 AM EDT
The two Hep C drugs are similar enough chemically to warrant caution.
07/30/12 - 07:00 AM EDT
Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.
07/23/12 - 07:00 AM EDT
Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.
07/16/12 - 07:07 AM EDT
TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.
07/10/12 - 08:10 AM EDT
With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.
06/28/12 - 11:38 AM EDT
TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.
06/25/12 - 11:13 AM EDT
Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.
06/18/12 - 07:00 AM EDT
An undervalued stock could move higher if Alkermes continues to grow through acquisitions.
06/11/12 - 07:09 AM EDT
Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.
06/04/12 - 07:45 AM EDT
Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.